One platform for all researcher needs
AI-powered academic writing assistant
Your #1 AI companion for literature search
AI tool for graphics, illustrations, and artwork
Unlock unlimited use of all AI tools with the Editage All Access membership.
Explore Editage All Access
Search from 250 M+ research papersSearch from 250 M+ research papers
Open Accesshttps://doi.org/10.1182/blood-2019-129024
Copy DOI Journal: Blood |  Publication Date: Nov 13, 2019 |
 Citations: 3 |
Affiliation: Nantes Université, Ziekenhuisnetwerk Antwerpen Stuivenberg, Instituto de Investigación Biomédica de Salamanca, Bristol-Myers Squibb (Switzerland), Tokyo National Hospital, The University of Texas MD Anderson Cancer Center, Centre Hospitalier de Vitré, Centre Hospitalier Annecy Genevois, Tokai University, Sarah Cannon, University Cancer Institute Toulouse Oncopole, Hôpitaux Universitaires Henri-Mondor, Claude Bernard University Lyon 1, Hospices Civils de Lyon, Hospital Clínic de Barcelona, Université Catholique de Louvain, Institute Paoli-Calmettes, Hôpital Saint-Louis, Centre Hospitalier Universitaire de Lille, Institut Gustave Roussy, Hôpital Lyon Sud, Memorial Sloan Kettering Cancer Center, Centre Hospitalier Départemental Vendée, University Hospital of Montpellier, University of Burgundy, Centre Hospitalier Métropole Savoie, Washington University in St. Louis, BC Cancer Agency, Centre Hospitalier Universitaire de Nancy, Seattle Cancer Care Alliance, Hôpital de l'Enfant-Jésus, Centre Hospitalier Universitaire de QuébecValidation of the PRIMA-Prognostic Index for Patients Treated with Rituximab Plus Chemotherapy and Refinement of Prognostic Parameters for Patients on Rituximab Plus Lenalidomide in the Phase III Relevance Trial
Sign-in/Register to access full text options 
Free) Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
